Horizon Therapeutics announced today that study results highlight the success of its Tepezza infusion for treating thyroid eye disease. Dublin, Ireland-based Horizon's Tepezza proved in pooled Phase 2 and Phase 3 clinical trial data that it … [Read More...] about Horizon touts data from trials for thyroid eye disease infusion treatment
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Another BD Alaris infusion pump recall is Class I
The FDA has identified another recall for the Alaris infusion pump from BD (NYSE:BDX) as Class I, the most serious kind of recall. BD's latest recall, initiated on March 3, 2021, involves its BD Alaris infusion pump module system, which includes … [Read More...] about Another BD Alaris infusion pump recall is Class I
Amgen completes $1.9B acquisition of Five Prime Therapeutics
Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share … [Read More...] about Amgen completes $1.9B acquisition of Five Prime Therapeutics
Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
Oncopeptides announced today that it submitted an application for European marketing authorization of its melflufen therapeutic. Conditional marketing authorization from the European Medicines Agency (EMA) is the aim for the company after its … [Read More...] about Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
Horizon touts data from trials for thyroid eye disease infusion treatment
Horizon Therapeutics announced today that study results highlight the success of its Tepezza infusion for treating thyroid eye disease. Dublin, Ireland-based Horizon's Tepezza proved in pooled Phase 2 and Phase 3 clinical trial data that it … [Read More...] about Horizon touts data from trials for thyroid eye disease infusion treatment
Genentech touts study results for spinal muscular atrophy drug in babies
Genentech today touted two-year data evaluating the use of its Evrysdi therapeutic in infants with symptomatic Type 1 spinal muscular atrophy (SMA). South San Francisco, Calif.-based Genentech's Firefish Phase 2/3 global study for Evrysdi … [Read More...] about Genentech touts study results for spinal muscular atrophy drug in babies
Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device
Innocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant. Athlone, Ireland-based Innocoll's trials are seeking label expansion for the FDA-approved Xaracoll … [Read More...] about Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device
Medtronic launches 7-day infusion set for diabetes in Europe
Medtronic (NYSE:MDT) announced today that it launched the Medtronic Extended infusion set for diabetes in select European countries. Fridley, Minn.–based Medtronic touts the Extended infusion set as the first and only infusion set that a diabetes … [Read More...] about Medtronic launches 7-day infusion set for diabetes in Europe
SciNeuro inks licenscing deal with Eli Lilly for targeted antibody therapies
SciNeuro Pharmaceuticals announced today that it entered into an exclusive licensing agreement with Eli Lilly for antibody therapies. Under the agreement, Shanghai-based SciNeuro obtained an exclusive license to develop and commercialize … [Read More...] about SciNeuro inks licenscing deal with Eli Lilly for targeted antibody therapies
CeQur raises $115M for wearable insulin delivery device
CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million. Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans … [Read More...] about CeQur raises $115M for wearable insulin delivery device
Terumo launches therapeutic interventional oncology team
Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team's introduction reflects its aspiration to be a global … [Read More...] about Terumo launches therapeutic interventional oncology team
In case you missed it
- GH Research closes $125M oversubscribed Series B
- BioCorp, Roche launch Mallya smart insulin pen in France
- Genentech wins FDA approval for Xolair prefilled syringe
- Lyra Therapeutics touts results from chronic rhinosinusitis treatment trial
- TriSalus, University of Texas to collaborate on solid tumor treatment study
- Teva Pharmaceuticals receives European approval for Spiromax inhalers
- Medtronic commits to helping people of color with diabetes
- Better Therapeutics to go public via $113M merger with SPAC
- Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine
- Kindeva, Cambridge Healthcare Innovations to collaborate on dry-powder inhaler
- Pear Therapeutics inks multiple agreements to expand digital therapeutic platform
- Seelos, Aptar sign deal for Bidose system to deliver ketamine candidate
- Nevro touts data supporting use of Senza system to treat diabetic neuropathy pain
- Amneal completes acquisition of Kashiv Specialty Pharmaceuticals
- Welldoc, Dexcom expand diabetes management tech partnership
Clinical Trials
Horizon touts data from trials for thyroid eye disease infusion treatment
Horizon Therapeutics announced today that study results highlight the success of its Tepezza infusion for treating thyroid eye disease. Dublin, Ireland-based Horizon’s Tepezza proved in pooled Phase 2 and Phase 3 clinical trial data that it significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a […]
Genentech touts study results for spinal muscular atrophy drug in babies
Genentech today touted two-year data evaluating the use of its Evrysdi therapeutic in infants with symptomatic Type 1 spinal muscular atrophy (SMA). South San Francisco, Calif.-based Genentech’s Firefish Phase 2/3 global study for Evrysdi (risdiplam) in infants between 1-7 months old showed that the orally administered (liquid or feeding tube) therapeutic continued to improve motor […]
Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device
Innocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant. Athlone, Ireland-based Innocoll’s trials are seeking label expansion for the FDA-approved Xaracoll (bupivacaine hydrochloride) implant, according to a news release. INN-CB-024, a Phase 3, randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety […]
Better Therapeutics initiates real-world study for digital therapeutic for diabetes
Better Therapeutics announced today that it commenced a real-world evidence study to evaluate its treatment for Type 2 diabetes. Collaborating with Steward Health Care, Better Therapeutics is evaluating BT-001, an investigational, prescription digital therapeutic (PDT) designed to deliver a novel form of cognitive-behavioral therapy to patients with uncontrolled Type 2 diabetes, according to a news […]
GH Research closes $125M oversubscribed Series B
GH Research Ireland announced that it closed an oversubscribed Series B financing round with proceeds of $125 million. Dublin, Ireland-based GH develops the GH001 therapeutic, a drug product for 5-MeO-DMT administration through a proprietary inhalation approach. A Phase 1 healthy volunteer trial showed GH001 to be well-tolerated while defining a dose range and individualized dosing […]
